
How Your Diet Influences Your Colorectal Cancer Risk
'It just didn't compute,' especially since she had always been healthy and active, said Ms. Kennedy, now 55, a communications consultant in Westwood, Mass.
There has been an alarming increase in colorectal cancer diagnoses in younger people, and it's now one of the top causes of cancer-related deaths in those under 50. Experts don't know what's causing the uptick, said Dr. Kimmie Ng, an oncologist and the director of the Young-Onset Colorectal Cancer Center at the Dana-Farber Cancer Institute. But at any age, factors like obesity, smoking, alcohol use, a lack of physical activity and a poor diet can increase the risk.
While other types of cancer have been associated with what people eat, colorectal cancer has a particularly strong link, Dr. Ng said. In a 2019 study, researchers estimated that nearly 40 percent of colorectal cancer cases in the United States could be traced back to poor diet.
That may be because food directly contacts 'the insides of our intestines,' Dr. Ng said, and it influences the balance of 'good' and 'bad' microbes in our guts.
Focus on fiber-rich whole foods.
Following a diet that prioritizes fruits, vegetables, whole grains, nuts and legumes can reduce your risk of colorectal cancer, said Dr. Edward Giovannucci, a professor of nutrition and epidemiology at the Harvard T.H. Chan School of Public Health.
Fiber is especially protective, said Dr. Heather Greenlee, a professor of cancer prevention at Fred Hutch Cancer Center in Seattle. You should aim for about 30 grams of fiber per day, she added. (You can get about that much in a day if you eat an apple and a cup each of broccoli, cooked quinoa and cooked lentils.) On average, adults in the United States consume about half as much.
Eating a variety of fiber-rich foods feeds your gut microbes and promotes the growth of more 'good' bacteria, which may outcompete certain 'bad' gut microbes that can produce toxins that damage DNA in the cells lining the colon and rectum.
Ms. Kennedy, who has been cancer free since 2019, was happy to learn that coffee — one of her 'favorite things in life' — was associated with a reduced risk of colorectal cancer. Coffee, tea, fruits and vegetables can be anti-inflammatory and may protect against the development of cancer or its recurrence, Dr. Ng said.
Get enough calcium.
Research suggests that calcium-rich foods like milk, yogurt, tofu and dark leafy greens can reduce your risk. Calcium may attach to certain harmful compounds in the gut, preventing them from damaging cells lining your colon and rectum, Dr. Giovannucci said.
In a study published this year of nearly 500,000 people aged 50 to 71 in the United States, those who consumed the most calcium from food and supplements had a 29 percent lower risk of developing colorectal cancer over more than 20 years than those who consumed the least amount of calcium.
The evidence linking calcium with a decreased risk of colorectal cancer is strongest when it comes from food, especially dairy products, but research suggests that calcium supplements may be similarly protective, Erikka Loftfield Cronin, an epidemiologist at the National Cancer Institute who led the calcium study, wrote in an email.
Experts recommend that most adults get around 1,000 to 1,200 milligrams of calcium per day. (You can get about 400 milligrams from a cup of yogurt or a half cup of tofu.)
Yogurt has the added benefit of containing probiotics, which may prevent certain 'bad' bacteria linked to colorectal cancer from taking up residence in your gut, Dr. Giovannucci said.
Limit alcohol, red and processed meats, and sugary drinks.
Alcohol can increase the risk of colorectal cancer and at least six other types of cancer. According to the American Cancer Society, it's best to not drink alcohol at all; if you do, they suggest limiting your consumption to no more than two drinks a day for men and one drink a day for women.
There's also evidence that regularly consuming processed meats like deli meats, bacon, jerky, sausages and hot dogs, as well as unprocessed red meats like beef, pork and lamb, increases the risk of cancer, especially when charred, smoked or cooked at high temperatures, said Carrie Daniel-MacDougall, a nutritional epidemiologist at MD Anderson Cancer Center in Texas.
According to one recent analysis, diets high in red meats were associated with a 30 percent increase in the risk of colorectal cancer, and those high in processed meats were associated with a 40 percent increase. Avoid processed meats as much as possible, Dr. Daniel-MacDougall said, and limit red meat to one serving per week. Choose fish, poultry, tofu or legumes instead, she said.
Dr. Daniel-MacDougall also suggested cutting back on ultraprocessed foods and drinks such as sugary sodas and most packaged desserts and snacks, which recent studies have linked to poor gut health and a greater risk of developing colorectal cancer. These foods often contain additives that may negatively affect the gut microbiome or the protective lining of the intestines, she said.
Ms. Kennedy now avoids most ultraprocessed foods. Cooking at home — with plenty of fresh vegetables, tofu, fish and yogurt — has become a passion. And she's given up red and processed meats entirely. 'A hamburger smells good on the grill,' she said, but 'the smell does it for me now.'
Diet is important, but it's not everything.
Experts recommend that most people get a colonoscopy or an at-home stool test, which can catch early signs of colorectal cancer and prevent it from developing further, starting at age 45.
For general health, federal officials recommend that adults get at least 150 minutes of moderate-intensity exercise per week, such as walking, jogging, biking or swimming, as well as strength training twice per week. Following that advice can reduce your risk of colorectal cancer, Dr. Greenlee said. A recent study found that physical activity also prevented new or recurring colon cancers in survivors.
Your risk of cancer develops over many years and is influenced by your genetics, too, experts said. There's no guarantee that eating well and exercising will prevent it, but they will likely cut your chances — and reduce your risk of heart disease, Type 2 diabetes and other health conditions, too.
'Everything that's good for colon cancer is actually good for overall health,' Dr. Giovannucci said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run
Key Points Hims & Hers Health is unlocking new sources of growth potential, and its balance sheet is flourishing. Doximity is a prime platform for advertisers, and the profits are pouring in. 10 stocks we like better than Hims & Hers Health › It's been a wild first half of the year for stocks in 2025, but finding the right companies for your portfolio is a very personal process. You need to consider the type of stocks you want to buy, the industries and sectors you gravitate toward, the amount of capital you have to invest, and your own personal risk tolerance. If you have cash to invest in the stock market right now, and you're looking for growth stocks that could make smart additions to the basket of businesses you own, there are names to be found across a range of industries, including healthcare. Here are two healthcare stocks that have at least doubled over the past 12 months but still look poised to deliver favorable returns for shareholders in the next three to five years. 1. Hims & Hers Health Hims & Hers Health (NYSE: HIMS) has witnessed a stock run-up of more than 200% over the trailing-12-month period. In contrast, the S&P 500 is up only about 18% in that same time frame. This boom in the company's share price has occurred for a few reasons. Investors were particularly excited about the company's ability to offer affordable, compounded GLP-1 drugs for weight loss amid shortages of branded versions, and that fueled significant revenue growth and share-price appreciation. However, Hims & Hers can no longer mass-produce compounded drugs like semaglutide because the U.S. Food and Drug Administration declared the shortage resolved. While the company may still offer personalized doses where clinically applicable, its primary weight loss offerings are shifting to oral medications and liraglutide. In fact, Novo Nordisk, the maker of Wegovy (semaglutide for weight) and Ozempic (semaglutide for diabetes), ended its partnership with Hims & Hers, citing concerns over the latter company's promotion and sales of compounded semaglutide. While the company's offerings may evolve in the coming months and years, it has other sources of growth to lean on besides the weight loss segment. Hims & Hers' areas of focus include sexual health, hair loss, dermatology, mental health, and primary care. The platform also provides access to both over-the-counter and prescription treatments via online consultations with licensed healthcare professionals, and most of its revenue still comes from recurring subscriptions paid by healthcare consumers. The recent acquisition of Zava, a European digital health platform, seems to have boosted investor confidence in the future of the business outside of its ambitions in the weight loss industry. The addition of Zava to Hims & Hers' ecosystem will expand its reach into the U.K., Ireland, France, and Germany. Hims & Hers also plans to launch its platform in Canada in 2026. Revenue grew by 110% year over year in the first quarter, and the company is building upon an improving track record of profitability. Hims & Hers also delivered free cash flow of about $50 million in Q1. This business has a lot of potential. 2. Doximity Doximity (NYSE: DOCS) has seen shares pop by a bit more than 100% since this time one year ago. Doximity is known as the largest digital platform for U.S. medical professionals. It serves as a professional and social network for healthcare professionals including doctors, nurse practitioners, and physician assistants, and offers a wide variety of tools for communication, news, and career management. Doximity provides a curated newsfeed with the latest medical news and research relevant to different specialties, and also offers tools for job searches, salary comparisons, and reputation management. The platform even provides telehealth solutions, enabling virtual patient visits and consultations. The platform is free for healthcare professionals to use. This free access includes Doximity Dialer, a feature that allows secure communication with patients using a customized calling tool. The platform also offers free digital fax lines and access to Doximity Scribe, an AI-powered note-taking tool for verified clinicians. So, how does Doximity make money? From advertising and selling information. Doximity's platform is a prime digital marketing and advertising tool for pharmaceutical manufacturers and healthcare systems (like hospitals). These entities pay Doximity to advertise and promote their products and services to targeted medical professionals. Health systems and medical recruiting firms also pay Doximity to access its database of medical professionals for recruitment and hiring purposes. In Doximity's fiscal 2025, which ended March 31, revenue increased 20% from the prior fiscal year to $570.4 million. The company reported net income of $223.2 million, up 51% year over year, with free cash flow spiking 50% to $266.7 million. This healthcare stock is really an advertising business at its core, and a profitable one at that. These factors could induce some investors to take another long look at this top stock and I think it has room to run. Do the experts think Hims & Hers Health is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Hims & Hers Health make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Rachel Warren has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Doximity and Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run was originally published by The Motley Fool 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤


Fox News
an hour ago
- Fox News
Deion Sanders says he never questioned God during his battle with bladder cancer
Deion Sanders revealed Monday he had his bladder removed after he was diagnosed with cancer, but he said he never questioned God, no matter how difficult things were. Sanders, 57, said God has blessed him too much to ask, 'Why me?' "I have never questioned God. You know my faith, man," Sanders said during an interview with Michael Irvin. "I never questioned and ask God. 'Why me?' I can't. Why me am I living like this? Why me am I the coach of the Colorado Buffaloes? Why me am I on this wonderful university? Why me do I have these wonderful kids with my last name? Like, why me that God has blessed me so much. Like, I would have to ask God, 'Why me all that, too?' "So, I never asked God, 'Why me?'" Sanders said he only asked the Lord to show him the way. "I only said, 'Lord, show me. Show me what you trying to do so I can help you expedite the process. Just show me. We got this, Lord. I know I ain't going nowhere,'" Sanders said. "I know for the enemy to try me, you had to say, 'Have you considered my servant crime?' You had to say that for him to even get to me. So I know that, I'm yours. I know what you going to do with me. I know what you going to continue to do with me." The bladder removal has forced Sanders to undergo a complete lifestyle change, which he said he reached out to someone for advice on how to deal with the changes. Sanders urged people to get checked, because he only discovered the cancer in the bladder after an ACT scan of his vascular pattern to determine if his blood clots were away. The Colorado head coach said it was "unbelievable" to be back talking to his players again. Colorado went 9-4 last season and will look to improve on that record this season after losing Heisman Trophy winner Travis Hunter and starting quarterback Shedeur Sanders to the NFL.
Yahoo
an hour ago
- Yahoo
Option Care Health, Inc. (OPCH): A Bull Case Theory
We came across a bullish thesis on Option Care Health, Inc. on Brian's Substack by Brian Flasker. In this article, we will summarize the bulls' thesis on OPCH. Option Care Health, Inc.'s share was trading at $29.35 as of July 31st. OPCH's trailing and forward P/E were 23.29 and 19.65, respectively according to Yahoo Finance. A home infusion nurse in full PPE gown delivering treatments to a patient in their own home. Option Care Health (OPCH) has evolved into the dominant independent provider of home and alternate site infusion services in the U.S., originating from Madison Dearborn Partners' 2015 acquisition of Walgreens Infusion Services. The 2019 reverse merger with BioScrip and full divestiture by Walgreens and MDP by 2023 paved the way for OPCH to operate with full independence. Led by CEO John Rademacher and CFO Michael Shapiro, both with substantial equity stakes, OPCH has built a national infrastructure of 91 pharmacies and 99 infusion suites, covering 96% of the U.S. population. The company's integrated model provides cost-effective, high-quality infusion therapies in outpatient and home settings, capitalizing on a healthcare trend shifting treatments away from costly hospitals. This platform serves over 1,400 contracts with 800+ partners, including all top 10 national insurers. Acute therapies, though operationally complex, act as a competitive wedge, while chronic therapies anchor long-term recurring revenues. OPCH's mix—75% chronic, 25% acute—combined with a focus on generics and biosimilars, ensures resilience against pricing volatility. With its Advanced Practitioner (AP) model, OPCH is pushing clinical boundaries, managing more complex therapies in lower-cost settings and enhancing utilization of its already-built infrastructure. Only ~50% of its infusion suite capacity is currently utilized, leaving ample runway for capital-light growth. Despite industry concerns like drug pricing reforms and labor shortages, OPCH's embedded relationships, clinical capabilities, and scalable model offer strong visibility into cash flow and earnings. Trading at ~15.4x 2025 owner earnings with a 17.4% expected IRR, OPCH represents a high-quality compounder with an entrenched moat and significant upside. Previously, we covered a bullish thesis on Chemed Corporation by 310 Value in April 2025, which highlighted the durability of its earnings, temporary volatility in its subsidiaries, and disciplined share repurchases. The company's stock price has depreciated by approximately 29% since our coverage. This is because temporary segment headwinds persisted longer than expected. The thesis still stands as Chemed's core fundamentals remain intact. Brian Flasker shares a similar view but emphasizes OPCH's capital-light model and payer-aligned infrastructure. Option Care Health, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 40 hedge fund portfolios held OPCH at the end of the first quarter, which was 40 in the previous quarter. While we acknowledge the potential of OPCH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data